221 related articles for article (PubMed ID: 34074152)
1. Deferoxamine to Minimize Fibrosis During Radiation Therapy.
Tevlin R; Longaker MT; Wan DC
Adv Wound Care (New Rochelle); 2022 Oct; 11(10):548-559. PubMed ID: 34074152
[No Abstract] [Full Text] [Related]
2. A comparative analysis of deferoxamine treatment modalities for dermal radiation-induced fibrosis.
Lavin CV; Abbas DB; Fahy EJ; Lee DK; Griffin M; Diaz Deleon NM; Mascharak S; Chen K; Momeni A; Gurtner GC; Longaker MT; Wan DC
J Cell Mol Med; 2021 Nov; 25(21):10028-10038. PubMed ID: 34612609
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic treatment with transdermal deferoxamine mitigates radiation-induced skin fibrosis.
Shen AH; Borrelli MR; Adem S; Deleon NMD; Patel RA; Mascharak S; Yen SJ; Sun BY; Taylor WL; Januszyk M; Nguyen DH; Momeni A; Gurtner GC; Longaker MT; Wan DC
Sci Rep; 2020 Jul; 10(1):12346. PubMed ID: 32704071
[TBL] [Abstract][Full Text] [Related]
4. Optimization of transdermal deferoxamine leads to enhanced efficacy in healing skin wounds.
Duscher D; Trotsyuk AA; Maan ZN; Kwon SH; Rodrigues M; Engel K; Stern-Buchbinder ZA; Bonham CA; Barrera J; Whittam AJ; Hu MS; Inayathullah M; Rajadas J; Gurtner GC
J Control Release; 2019 Aug; 308():232-239. PubMed ID: 31299261
[TBL] [Abstract][Full Text] [Related]
5. Chelating the valley of death: Deferoxamine's path from bench to wound clinic.
Parker JB; Griffin MF; Downer MA; Akras D; Berry CE; Cotterell AC; Gurtner GC; Longaker MT; Wan DC
Front Med (Lausanne); 2023; 10():1015711. PubMed ID: 36873870
[TBL] [Abstract][Full Text] [Related]
6. Transdermal deferoxamine prevents pressure-induced diabetic ulcers.
Duscher D; Neofytou E; Wong VW; Maan ZN; Rennert RC; Inayathullah M; Januszyk M; Rodrigues M; Malkovskiy AV; Whitmore AJ; Walmsley GG; Galvez MG; Whittam AJ; Brownlee M; Rajadas J; Gurtner GC
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):94-9. PubMed ID: 25535360
[TBL] [Abstract][Full Text] [Related]
7. Transdermal deferoxamine administration improves excisional wound healing in chronically irradiated murine skin.
Lintel H; Abbas DB; Lavin CV; Griffin M; Guo JL; Guardino N; Churukian A; Gurtner GC; Momeni A; Longaker MT; Wan DC
J Transl Med; 2022 Jun; 20(1):274. PubMed ID: 35715816
[TBL] [Abstract][Full Text] [Related]
8. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Farr AC; Xiong MP
Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
[TBL] [Abstract][Full Text] [Related]
10. Topical Deferoxamine Alleviates Skin Injury and Normalizes Atomic Force Microscopy Patterns Following Radiation in a Murine Breast Reconstruction Model.
Snider AE; Lynn JV; Urlaub KM; Donneys A; Polyatskaya Y; Nelson NS; Ettinger RE; Gurtner GC; Banaszak Holl MM; Buchman SR
Ann Plast Surg; 2018 Nov; 81(5):604-608. PubMed ID: 30113984
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
Ikeda Y; Ozono I; Tajima S; Imao M; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
PLoS One; 2014; 9(2):e89355. PubMed ID: 24586712
[TBL] [Abstract][Full Text] [Related]
12. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
13. Iron Chelation with Transdermal Deferoxamine Accelerates Healing of Murine Sickle Cell Ulcers.
Rodrigues M; Bonham CA; Minniti CP; Gupta K; Longaker MT; Gurtner GC
Adv Wound Care (New Rochelle); 2018 Oct; 7(10):323-332. PubMed ID: 30374417
[No Abstract] [Full Text] [Related]
14. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
15. Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats.
Feng Y; Jia L; Ma W; Tian C; Du H
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627331
[TBL] [Abstract][Full Text] [Related]
16. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
17. Dextran-coupled deferoxamine improves outcome in a murine model of head injury.
Panter SS; Braughler JM; Hall ED
J Neurotrauma; 1992; 9(1):47-53. PubMed ID: 1377753
[TBL] [Abstract][Full Text] [Related]
18. The effects of conjugated deferoxamine in porcine skin flaps.
Hom DB; Goding GS; Price JA; Pernell KJ; Maisel RH
Head Neck; 2000 Sep; 22(6):579-84. PubMed ID: 10941159
[TBL] [Abstract][Full Text] [Related]
19. Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage.
Guo X; Qi X; Li H; Duan Z; Wei Y; Zhang F; Tian M; Ma L; You C
World Neurosurg; 2019 Aug; 128():e895-e904. PubMed ID: 31082547
[TBL] [Abstract][Full Text] [Related]
20. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Choudry K; Brooke RC; Farrar W; Rhodes LE
Br J Dermatol; 2003 Jul; 149(1):124-30. PubMed ID: 12890205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
